The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice

摘要: Objective Psoriasis is one of the most common forms chronic dermatitis, affecting 2–3% worldwide popula-tion. It has a serious effect on way patients perceive themselves and others, thereby prejudicing their quality life giving rise to significant deterioration in psycho-physical well-being; it also poses greater difficulties for them leading normal social life, including ability conduct working life. All above-mentioned issues imply cost society. This study proposes evaluate impact societal costs treatment plaque psoriasis with biologics (etanercept, infliximab adalimumab) Italian clinical practice. Method A prospective observational been conducted 12 specialized centres Psocare network, located throughout Italy. Direct indirect (as well as health-related under-going biologic treatments) have estimated, while determined using cost-utility approach. Results Non-medical account much 44.97% total prior 6.59% after treatment, an overall 71.38% decrease. Adopting perspective actual practice participating centres, ICER therapies treating amounted €18634.40 per QALY gained – value far from €28656.30 obtained by adopting third-party payer perspective. Conclusion Our confirms that subjects considerable burden, together families caregivers, stressing how important take into consideration during appraisal process. Besides, data derived practice, shows noteworthy benefit terms. Received: 25 February 2015; Accepted: 18 May 2015